Across party lines, Americans generally agree that prescription drug prices in the US are unreasonable. But those high domestic drug prices are part of an incentive structure that drives global pharmaceutical innovation. So how can lawmakers balance the priorities of lowering drug prices and maximizing innovation? This post reviews how France and England factor these concerns into their unique approaches to prescription drug pricing.